Cyxone Ab Stock Fundamentals
| CYXO Stock | SEK 0.03 0 11.11% |
Cyxone AB fundamentals help investors to digest information that contributes to Cyxone AB's financial success or failures. It also enables traders to predict the movement of Cyxone Stock. The fundamental analysis module provides a way to measure Cyxone AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyxone AB stock.
Cyxone |
Cyxone AB Company Shares Outstanding Analysis
Cyxone AB's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cyxone AB Shares Outstanding | 98.44 M |
Most of Cyxone AB's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyxone AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Cyxone AB has 98.44 M of shares currently outstending. This is 45.47% lower than that of the Healthcare sector and 7.87% lower than that of the Biotechnology industry. The shares outstanding for all Sweden stocks is 82.78% higher than that of the company.
Cyxone AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cyxone AB's current stock value. Our valuation model uses many indicators to compare Cyxone AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyxone AB competition to find correlations between indicators driving Cyxone AB's intrinsic value. More Info.Cyxone AB is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyxone AB's earnings, one of the primary drivers of an investment's value.Cyxone Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyxone AB's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyxone AB could also be used in its relative valuation, which is a method of valuing Cyxone AB by comparing valuation metrics of similar companies.Cyxone AB is currently under evaluation in shares outstanding category among its peers.
Cyxone Fundamentals
| Return On Equity | -1.07 | |||
| Return On Asset | -0.59 | |||
| Current Valuation | 7.74 M | |||
| Shares Outstanding | 98.44 M | |||
| Shares Owned By Insiders | 25.38 % | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5,168 X | |||
| EBITDA | (43.23 M) | |||
| Net Income | (45.03 M) | |||
| Cash And Equivalents | 56.34 M | |||
| Cash Per Share | 0.97 X | |||
| Current Ratio | 11.35 X | |||
| Book Value Per Share | 0.50 X | |||
| Cash Flow From Operations | (43.25 M) | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 4.2 | |||
| Beta | 0.54 | |||
| Market Capitalization | 52.96 M | |||
| Total Asset | 46.13 M | |||
| Net Asset | 46.13 M |
About Cyxone AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyxone AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyxone AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyxone AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Cyxone AB , a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis and treatments for virally induced acute respiratory disorders. The company was founded in 2015 and is headquartered in Malm, Sweden. Cyxone AB is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.